Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines

Item Type:

Publication

Title

Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines

Description

Emerging and re-emerging infectious diseases pose growing global public health threats.

Source

Nahid Bhadelia, Lauren Sauer, Theodore J. Cieslak, Richard T. Davey, Susan McLellan, Timothy M. Uyeki, Mark G. Kortepeter, writing on behalf of National Ebola Training and Education Center's Special Pathogens Research Network (SPRN)'s Medical Countermeasures Working Group, Mary Akers, Kerry Dierberg, Dan Eiras, Jared Evans, Elena Figueroa, Colleen Kraft, Chris Kratochvil, Karen Martins, Greg Measer, Aneesh Mehta, Jean Hu-Primmer, and George Risi.

Date Last Updated (Year-Month-Day)

2019-02-06

Citation

Nahid Bhadelia, Lauren Sauer, Theodore J. Cieslak, Richard T. Davey, Susan McLellan, Timothy M. Uyeki, Mark G. Kortepeter, writing on behalf of National Ebola Training and Education Center's Special Pathogens Research Network (SPRN)'s Medical Countermeasures Working Group, Mary Akers, Kerry Dierberg, Dan Eiras, Jared Evans, Elena Figueroa, Colleen Kraft, Chris Kratochvil, Karen Martins, Greg Measer, Aneesh Mehta, Jean Hu-Primmer, and George Risi. 2019. Health Security. http://doi.org/10.1089/hs.2018.0092

Abstract

Abstract

Emerging and re-emerging infectious diseases pose growing global public health threats. However, research on and development of medical countermeasures (MCMs) for such pathogens is limited by the sporadic and unpredictable nature of outbreaks, lack of financial incentive for pharmaceutical companies to develop interventions for many of the diseases, lack of clinical research capacity in areas where these diseases are endemic, and the ethical dilemmas related to conducting scientific research in humanitarian emergencies. Hence, clinicians providing care for patients with emerging diseases are often faced with making clinical decisions about the safety and effectiveness of experimental MCMs, based on limited or no human safety, preclinical, or even earlier product research or historical data, for compassionate use. Such decisions can have immense impact on current and subsequent patients, the public health response, and success of future clinical trials. We highlight these dilemmas and underscore the need to proactively set up procedures that allow early and ethical deployment of MCMs as part of clinical trials. When clinical trials remain difficult to deploy, we present several suggestions of how compassionate use of off-label and unlicensed MCMs can be made more informed and ethical. We highlight several collaborations seeking to address these gaps in data and procedures to inform future clinical and public health decision making.

Accessibility

Online Ahead of Print: February 6, 2019

Share this page: